Insider Ledger
Disc Medicine, Inc. (IRON) insider buying and SEC filings
Disc Medicine, Inc. · CIK 1816736
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- Fiscal year end
- Dec 31
- Former names
- Gemini Therapeutics, Inc. /DE; FS Development Corp.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$18.7M
Planned sales (10b5-1)
$29.4M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 19–21, 2026 | Planned (10b5-1) | Kevin Bitterman (Director) sold 41,825 shares indirectly between Oct 19 and Oct 21 at about $80.13 ($3.4M), marked as a 10b5-1 plan trade. Indirect holdings down 76% to 12,991 shares. | SEC filing Filed Oct 21, 2026, 5:33 PM ET |
| Sep 4, 2026 | Planned (10b5-1) | Kevin Bitterman (Director) sold 1,689 shares indirectly at about $79.96 ($135K), marked as a 10b5-1 plan trade. Indirect holdings down 11% to 13,427 shares. | SEC filing Filed Sep 9, 2026 |
| Sep 1–3, 2026 | Planned (10b5-1) | Kevin Bitterman (Director) sold 54,496 shares indirectly between Sep 1 and Sep 3 at about $80.15 ($4.4M), marked as a 10b5-1 plan trade. Indirect holdings down 80% to 13,445 shares. | SEC filing Filed Sep 3, 2026 |
| Aug 24–25, 2026 | Planned (10b5-1) | Jonathan Yen-Wen Yu (President / COO) sold 9,096 shares between Aug 24 and Aug 25 at about $83.10 ($756K), marked as a 10b5-1 plan trade. Holdings down 14% to 54,324 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | John D Quisel (CEO and Director) sold 33,000 shares at about $79.15 ($2.6M), marked as a 10b5-1 plan trade. Holdings down 13% to 226,064 shares. | SEC filing Filed Aug 18, 2026 |
| Aug 12, 2026 | Planned (10b5-1) | Jonathan Yen-Wen Yu (President / COO) sold 804 shares at about $82.64 ($66K), marked as a 10b5-1 plan trade. Holdings down 1% to 54,324 shares. | SEC filing Filed Aug 14, 2026 |
| Aug 6, 2026 | Planned (10b5-1) | Rahul Khara (Chief Legal Officer) sold 5,000 shares at $80.00 ($400K), marked as a 10b5-1 plan trade. Holdings down 9% to 52,324 shares. | SEC filing Filed Aug 7, 2026 |
| Jul 13, 2026 | Planned (10b5-1) | John D Quisel (CEO and Director) sold 33,000 shares at about $74.96 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 13% to 226,064 shares. | SEC filing Filed Jul 14, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | Jonathan Yen-Wen Yu (President / COO) sold 100 shares at $82.50 ($8K), marked as a 10b5-1 plan trade. Holdings down <1% to 54,324 shares. | SEC filing Filed Jul 9, 2026 |
| Jun 26–29, 2026 | Planned (10b5-1) | Rahul Khara (Chief Legal Officer) sold 2,500 shares between Jun 26 and Jun 29 at $75.00 ($188K), marked as a 10b5-1 plan trade. Holdings down 5% to 52,173 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | Jonathan Yen-Wen Yu (President / COO) sold 300 shares at $72.50 ($22K), marked as a 10b5-1 plan trade. Holdings down 1% to 54,324 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Jonathan Yen-Wen Yu (President / COO) sold 9,700 shares at about $72.66 ($705K), marked as a 10b5-1 plan trade. Holdings down 15% to 54,324 shares. | SEC filing Filed Jun 24, 2026 |
| Jun 18, 2026 | Planned (10b5-1) | Rahul Khara (Chief Legal Officer) sold 7,500 shares at about $70.22 ($527K), marked as a 10b5-1 plan trade. Holdings down 13% to 52,173 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 18, 2026 | Planned (10b5-1) | John D Quisel (CEO and Director) sold 34,000 shares at about $70.22 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 13% to 226,064 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 16, 2026 | Planned (10b5-1) | Jonathan Yen-Wen Yu (President / COO) sold 18,612 shares at about $69.19 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 26% to 54,324 shares. | SEC filing Filed Jun 18, 2026 |
| Apr 13, 2026 | Planned (10b5-1) | William Jacob Savage (Chief Medical Officer) sold 5,731 shares at about $66.38 ($380K), marked as a 10b5-1 plan trade. Holdings down 7% to 79,480 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 13–14, 2026 | Planned (10b5-1) | Jean M. Franchi (CFO) sold 6,657 shares between Apr 13 and Apr 14 at about $69.23 ($461K), marked as a 10b5-1 plan trade. Holdings down 9% to 64,333 shares. | SEC filing Filed Apr 15, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | William Jacob Savage (Chief Medical Officer) sold 7,378 shares at about $65.88 ($486K), marked as a 10b5-1 plan trade. Holdings down 8% to 85,211 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Jean M. Franchi (CFO) sold 353 shares at about $69.06 ($24K), marked as a 10b5-1 plan trade. Holdings down <1% to 70,990 shares. | SEC filing Filed Feb 27, 2026 |
| Feb 17–18, 2026 | Planned (10b5-1) | Jean M. Franchi (CFO) sold 11,156 shares between Feb 17 and Feb 18 at about $64.52 ($720K), marked as a 10b5-1 plan trade. Holdings down 14% to 71,343 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 17, 2026 | Sale | Rahul Khara (Chief Legal Officer) sold 2,853 shares at $62.86 ($179K). Holdings down 5% to 52,173 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Feb 17, 2026 | Sale | Pamela Stephenson (Chief Commercial Officer) sold 5,531 shares at $62.86 ($348K). Holdings down 6% to 80,998 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Feb 17, 2026 | Sale | William Jacob Savage (Chief Medical Officer) sold 3,256 shares at $62.86 ($205K). Holdings down 3% to 92,589 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Feb 17, 2026 | Sale | Jonathan Yen-Wen Yu (President / COO) sold 3,231 shares at $62.86 ($203K). Holdings down 6% to 54,324 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Feb 17, 2026 | Sale | John D Quisel (CEO and Director) sold 13,264 shares at $62.86 ($834K). Holdings down 6% to 226,064 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Rahul Khara (Chief Legal Officer) sold 1,000 shares at $69.74 ($70K), marked as a 10b5-1 plan trade. Holdings down 3% to 37,793 shares. | SEC filing Filed Jan 21, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Rahul Khara (Chief Legal Officer) sold 6,500 shares at about $78.68 ($511K), marked as a 10b5-1 plan trade. Holdings down 15% to 37,793 shares. | SEC filing Filed Jan 5, 2026 |
| Dec 17, 2025 | Sale | Kevin Bitterman (Director) sold 754 shares indirectly at about $91.47 ($69K). Indirect holdings down 5% to 14,013 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 18, 2025 |
| Dec 15, 2025 | Planned (10b5-1) | William Jacob Savage (Chief Medical Officer) sold 13,093 shares at about $91.22 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 15% to 75,702 shares. | SEC filing Filed Dec 16, 2025 |
| Dec 12–16, 2025 | Sale | Kevin Bitterman (Director) sold 184,123 shares directly and indirectly between Dec 12, 2025 and Dec 16, 2025 at about $91.56 ($16.9M). Direct holdings down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 16, 2025 |
| Dec 11, 2025 | Planned (10b5-1) | John D Quisel (CEO and Director) sold 40,000 shares at about $93.05 ($3.7M), marked as a 10b5-1 plan trade. Holdings down 19% to 171,828 shares. | SEC filing Filed Dec 15, 2025 |
| Nov 11, 2025 | Planned (10b5-1) | Jonathan Yen-Wen Yu (President / COO) sold 30,000 shares at about $84.70 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 43% to 40,555 shares. | SEC filing Filed Nov 13, 2025 |
35 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow IRON in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.